900 related articles for article (PubMed ID: 30196031)
1. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.
Galimberti V; Cole BF; Viale G; Veronesi P; Vicini E; Intra M; Mazzarol G; Massarut S; Zgajnar J; Taffurelli M; Littlejohn D; Knauer M; Tondini C; Di Leo A; Colleoni M; Regan MM; Coates AS; Gelber RD; Goldhirsch A;
Lancet Oncol; 2018 Oct; 19(10):1385-1393. PubMed ID: 30196031
[TBL] [Abstract][Full Text] [Related]
2. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.
Galimberti V; Cole BF; Zurrida S; Viale G; Luini A; Veronesi P; Baratella P; Chifu C; Sargenti M; Intra M; Gentilini O; Mastropasqua MG; Mazzarol G; Massarut S; Garbay JR; Zgajnar J; Galatius H; Recalcati A; Littlejohn D; Bamert M; Colleoni M; Price KN; Regan MM; Goldhirsch A; Coates AS; Gelber RD; Veronesi U;
Lancet Oncol; 2013 Apr; 14(4):297-305. PubMed ID: 23491275
[TBL] [Abstract][Full Text] [Related]
3. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial.
Leiter U; Stadler R; Mauch C; Hohenberger W; Brockmeyer N; Berking C; Sunderkötter C; Kaatz M; Schulte KW; Lehmann P; Vogt T; Ulrich J; Herbst R; Gehring W; Simon JC; Keim U; Martus P; Garbe C;
Lancet Oncol; 2016 Jun; 17(6):757-767. PubMed ID: 27161539
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.
Donker M; van Tienhoven G; Straver ME; Meijnen P; van de Velde CJ; Mansel RE; Cataliotti L; Westenberg AH; Klinkenbijl JH; Orzalesi L; Bouma WH; van der Mijle HC; Nieuwenhuijzen GA; Veltkamp SC; Slaets L; Duez NJ; de Graaf PW; van Dalen T; Marinelli A; Rijna H; Snoj M; Bundred NJ; Merkus JW; Belkacemi Y; Petignat P; Schinagl DA; Coens C; Messina CG; Bogaerts J; Rutgers EJ
Lancet Oncol; 2014 Nov; 15(12):1303-10. PubMed ID: 25439688
[TBL] [Abstract][Full Text] [Related]
5. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
[TBL] [Abstract][Full Text] [Related]
6. Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial.
Andersson Y; Bergkvist L; Frisell J; de Boniface J
Br J Surg; 2021 Sep; 108(9):1105-1111. PubMed ID: 34010418
[TBL] [Abstract][Full Text] [Related]
7. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.
Krag DN; Anderson SJ; Julian TB; Brown AM; Harlow SP; Costantino JP; Ashikaga T; Weaver DL; Mamounas EP; Jalovec LM; Frazier TG; Noyes RD; Robidoux A; Scarth HM; Wolmark N
Lancet Oncol; 2010 Oct; 11(10):927-33. PubMed ID: 20863759
[TBL] [Abstract][Full Text] [Related]
8. Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment.
Tinterri C; Canavese G; Gatzemeier W; Barbieri E; Bottini A; Sagona A; Caraceni G; Testori A; Di Maria Grimaldi S; Dani C; Boni L; Bruzzi P; Fernandes B; Scorsetti M; Zambelli A; Gentile D;
Br J Surg; 2023 Aug; 110(9):1143-1152. PubMed ID: 37471574
[TBL] [Abstract][Full Text] [Related]
9. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of sentinel lymph node micrometastases in patients with invasive breast carcinoma.
Cipolla C; Graceffa G; La Mendola R; Fricano S; Fricano M; Vieni S
Ann Ital Chir; 2015; 86():497-502. PubMed ID: 26898168
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
[TBL] [Abstract][Full Text] [Related]
12. Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study.
Hennigs A; Riedel F; Feißt M; Köpke M; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Heil J
Ann Surg Oncol; 2019 Aug; 26(8):2435-2443. PubMed ID: 31049766
[TBL] [Abstract][Full Text] [Related]
13. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.
Badwe R; Hawaldar R; Nair N; Kaushik R; Parmar V; Siddique S; Budrukkar A; Mittra I; Gupta S
Lancet Oncol; 2015 Oct; 16(13):1380-8. PubMed ID: 26363985
[TBL] [Abstract][Full Text] [Related]
14. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
[TBL] [Abstract][Full Text] [Related]
15. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.
Henke G; Knauer M; Ribi K; Hayoz S; Gérard MA; Ruhstaller T; Zwahlen DR; Muenst S; Ackerknecht M; Hawle H; Fitzal F; Gnant M; Mátrai Z; Ballardini B; Gyr A; Kurzeder C; Weber WP
Trials; 2018 Dec; 19(1):667. PubMed ID: 30514362
[TBL] [Abstract][Full Text] [Related]
16. Recommendation for axillary lymph node dissection in women with early breast cancer and sentinel node metastasis: A systematic review and meta-analysis of randomized controlled trials using the GRADE system.
Huang TW; Kuo KN; Chen KH; Chen C; Hou WH; Lee WH; Chao TY; Tsai JT; Su CM; Huang MT; Tam KW
Int J Surg; 2016 Oct; 34():73-80. PubMed ID: 27562691
[TBL] [Abstract][Full Text] [Related]
17. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
[TBL] [Abstract][Full Text] [Related]
18. Role of frozen section in sentinel lymph node biopsy for breast cancer in the era of the ACOSOG Z0011 and IBCSG 23-10 trials.
Lombardi A; Nigri G; Maggi S; Stanzani G; Vitale V; Vecchione A; Nania A; Amanti C
Surgeon; 2018 Aug; 16(4):232-236. PubMed ID: 29329752
[TBL] [Abstract][Full Text] [Related]
19. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
[TBL] [Abstract][Full Text] [Related]
20. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial.
de Boniface J; Frisell J; Andersson Y; Bergkvist L; Ahlgren J; Rydén L; Olofsson Bagge R; Sund M; Johansson H; Lundstedt D;
BMC Cancer; 2017 May; 17(1):379. PubMed ID: 28549453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
